RXRX icon

Recursion Pharmaceuticals
RXRX

Upgrade to unlock
Buy
Hold
Sell

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$7
87% upside
High target

2 analyst ratings

positive
1  neutral
50%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
BofA Securities
BofA Securities
Michael Ryskin
26 Feb ‘26 1 month ago
Needham
Needham
Gil Blum
40% 1-yr RXRX win rate
26 Feb ‘26 1 month ago